Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Tobacco smoking cessation management: integrating varenicline in current practice

Authors Laurence M Galanti

Published 8 August 2008 Volume 2008:4(4) Pages 837—845

DOI http://dx.doi.org/10.2147/VHRM.S3250

Review by Single-blind

Peer reviewer comments 3

Laurence M Galanti

Clinique Universitaire UCL, Mont-Godinne, Yvoir, Belgium

Abstract: Tobacco smoking is widespread and is one of the world’s most prevalent modifiable risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in order to reduce the health consequences of tobacco use. The most effective approach assisting smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interventions. This review summarizes the latest international epidemiological data available on tobacco use, considers the associated effects on health, and reviews existing policies against tobacco use. Among the interventions for smoking cessation, the three major pharmacotherapies (which have demonstrated efficacy when combined with behavioral support) are discussed: nicotine replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made available in this area, particular consideration is given to varenicline, and a review of our clinical experience is offered.

Keywords: tobacco smoking cessation, nicotinic substitution, nicotine replacement therapy (NRT), bupropion, varenicline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

High expression of HEF1 is associated with poor prognosis in urinary bladder carcinoma

Zhang Q, Wang HJ, Zhang DH, Ru GQ, He XJ, Ma YY

OncoTargets and Therapy 2014, 7:1319-1326

Published Date: 21 July 2014

Modern role for clopidogrel in management of atrial fibrillation and stroke reduction

Lars Maegdefessel, Junya Azuma, Philip S Tsao

Vascular Health and Risk Management 2010, 6:95-103

Published Date: 26 February 2010

Potential of liraglutide in the treatment of patients with type 2 diabetes

Carolyn F Deacon

Vascular Health and Risk Management 2009, 5:199-211

Published Date: 2 February 2009

The trabecular bypass stent in a pseudophakic glaucoma patient: A 1-year follow-up

Antonio M Fea, Monica Dogliani, Federica Machetta, Gabriella Lale-Lacroix, Beatrice Brogliatti, Federico MGrignolo

Clinical Ophthalmology 2008, 2:931-934

Published Date: 5 December 2008

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

Marc K Israel, Eva Istvan, Michelle A Baron

Vascular Health and Risk Management 2008, 4:1167-1178

Published Date: 5 December 2008

Vascular risk factors, cognitve decline, and dementia

E Duron, Olivier Hanon

Vascular Health and Risk Management 2008, 4:363-381

Published Date: 11 April 2008

In the aftermath of the Fusarium keratitis outbreak: What have we learned?

Arthur B Epstein

Clinical Ophthalmology 2007, 1:355-366

Published Date: 15 February 2008

Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction

Lena Björck, Catharina Welin, Annika Rosengren

Vascular Health and Risk Management 2007, 3:1045-1051

Published Date: 15 January 2008

Editorial: What future for vascular neurosurgery? || FREE PAPER ||

Matthew Crocker, Christos Tolias

Vascular Health and Risk Management 2007, 3:243-244

Published Date: 15 July 2007